English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Purpose  The authors previously revealed the association of the follicular fluid ( FF ) volume with oolemma stretchability following the gonadotropin‐releasing hormone (Gn RH ) antagonist protocol during intracytoplasmic sperm injection ( ICSI ). However, the impact of the Gn RH  agonist protocol on oolemma stretchability remains unclear.    Methods  Data that were obtained from 74  ICSI  cycles were reviewed retrospectively. Controlled ovarian stimulation was performed in accordance with the short Gn RH  agonist protocol. Each follicle was individually aspirated and assigned to one of six groups, according to the  FF  volume. The oolemma stretchability during  ICSI  was evaluated by using a mechanical stimulus for oolemma penetration; that is, oolemma penetration with or without aspiration (high vs low stretchability, respectively).    Results  The incidence of low oolemma stretchability was significantly higher in the <1.0  mL  group than that in the ≥1.0  mL  group. The normal fertilization rate was significantly lower in the <1.0  mL  group than that in the 2.0‐<3.0  mL  group. The rate of blastocyst development was lower in the <1.0  mL  group than that in the 3.0‐<4.0  mL  group.    Conclusion  The  FF  volume potentially was associated with metaphase  II  oolemma stretchability, fertilization, and blastocyst development.

reproductive medicine and biology

Association of follicular fluid volume with membrane stretchability of human metaphase  II  oocytes following the gonadotropin‐releasing hormone agonist protocol during intracytoplasmic sperm injection